ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1280

Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors

Edward Keystone1, Stanley B. Cohen2, Paul Emery3, Joel M. Kremer4, Maxime R. Dougados5, James E. Loveless6, Carol Chung7, Pamela Wong7, Patrica B. Lehane8 and Helen Tyrrell8, 1The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, 2Metroplex Clinical Research Center, Dallas, TX, 3Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 4Center for Rheumatology, Albany Medical College, Albany, NY, 5Hopital Cochin, René Descartes University, Paris, France, 6St Luke's Rheumatology, Boise, ID, 7Genentech, Inc., South San Francisco, CA, 8Roche Products Limited, Welwyn Garden City, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: In the REFLEX study conducted in anti-TNF inadequate responder (TNF-IR) patients with RA, a single course of rituximab (RTX) in combination with methotrexate (MTX) significantly improved disease activity at 24 weeks vs placebo (PBO) + MTX. Patients were eligible for continued RTX treatment in an open-label extension (OLE). Efficacy and safety outcomes from REFLEX and its OLE over 5 years are presented.

Methods: This was an observational, post-hoc analysis of REFLEX from baseline to 5 years, open label from the second study treatment. Patients originally randomized to PBO were rescued with RTX as appropriate and included in the OLE. Patients with a response to initial RTX treatment were eligible for further RTX treatment courses. RTX retreatment was administered as needed based on SJC and TJC ≥8 and at the discretion of the physician (≥24 weeks following first RTX course and ≥16 weeks following additional courses). PBO patients were re-baselined prior to their first RTX treatment and for this analysis PBO data were pooled with RTX patient data from time of first RTX treatment. Efficacy outcomes 24 weeks after each RTX course were calculated relative to first RTX pre-treatment baseline. No imputations were made for missing data. Safety data included rates of AEs, serious AEs (SAEs), infections, and serious infections (SIEs).

Results: Overall, 480 patients received at least one course of RTX. Subsequent RTX courses were given to 317 (≥2 courses), 259 (≥3 courses), 195 (≥4 courses), and 122 (≥5 courses) patients. Most withdrawals occurred after course 1, mainly for non-safety reasons. ACR responses were improved after the first course of RTX and were maintained over 5 courses (Table) with a similar trend observed for EULAR responses.

ACR response rates (% patients) at 24 weeks after each course
Clinical measure Course 1
(n=400)
Course 2
(n=279)
Course 3
(n=225)
Course 4
(n=161)
Course 5
(n=91)
ACR20 62.0 72.8 72.4 65.8 70.3
ACR50 30.8 41.2 47.6 44.7 41.8
ACR70 13.0 19.4 26.2 24.2 22.0

The proportion of patients achieving a minimal clinically important difference in HAQ-DI was maintained over 5 courses (66.0–71.1%). Over the 5 years, rates of AEs, SAEs, and infections did not increase and generally remained stable in the RTX-treated population (1768 pt-yrs), with overall rates per 100 pt-yrs (95% CI) of 344.87 (336.32–353.64) for AEs, 22.34 (20.24–24.65) for SAEs, 97.50 (93.01–102.21) for all infections, and 5.60 (4.60–6.82) for SIEs. The most frequent SIE was pneumonia, affecting 2% of RTX patients.

Conclusion: This post-hoc analysis shows that RTX repeat treatment is associated with 24-week clinical efficacy responses, sustained to 5 courses, with a trend towards improved efficacy over time. The safety profile of RTX was comparable with published RTX long-term safety data and with that of other biologics in RA populations. No increased incidence of significant AEs was observed in spite of RTX exposure and peripheral B-cell depletion over many years. The results confirm RTX as an effective long-term treatment option in this refractory RA population.


Disclosure:

E. Keystone,

Abbott, Amgen, AstraZeneca, Bristol-Meyers Squibb, Centocor, Roche, Genzyme, Merck, Novartis, Pfizer, UCB,

2,

Abbott, AstraZeneca, Biotest, Bristol-Meyers Squibb, Centocor, Roche, Genentech, Merck, Nycomed, Pfizer, UCB,

5;

S. B. Cohen,

Abbott, Amgen, AstraZeneca, Bristol-Meyers Squibb, Centocor, Roche, Genzyme, Merck, Novartis, Pfizer, UCB,

2,

Amgen, Bristol-Meyers Squibb, Roche/Genentech, Merck, Pfizer,

5;

P. Emery,

Pfizer, Merck, Abbott, BMS, Roche, UCB,

5;

J. M. Kremer,

Roche, Genentech,

2,

Genentech,

5;

M. R. Dougados,

Roche, Abbott, Pfizer, BMS, UCB, Novartis, Merck,

2,

Roche, Abbott, Pfizer, BMS, UCB, Novartis, Merck,

5;

J. E. Loveless,

Roche,

2,

Roche, Genentech,

5,

Roche,

8;

C. Chung,

Genentech, Inc (full time),

3;

P. Wong,

Genentech, Inc (full time),

3;

P. B. Lehane,

Roche,

3;

H. Tyrrell,

Roche ,

1,

Roche,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-efficacy-responses-and-a-consistent-safety-profile-with-rituximab-repeat-treatment-over-5-years-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-tumour-necrosis-factor-inh/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology